Analytical and clinical validation of a <scp>NGS</scp> panel in detecting targetable variants from <scp>ctDNA</scp> of metastatic <scp>NSCLC</scp> patients
The ctDNA-based 101-test is a highly sensitive and specific tool for detecting targetable variants in metastatic NSCLC, particularly in cases with insufficient tissue samples. The findings support the use of ctDNA testing as a reliable and complementary method to traditional tissue-based molecular analysis, enhancing the precision of treatment strategies for NSCLC patients.
Authors
- Juan Lv (ORCID: https://orcid.org/0000-0002-0545-5448)
- Guozhong Jiang (ORCID: https://orcid.org/0000-0001-6306-726X)
- Haiwei Du (ORCID: https://orcid.org/0000-0002-4329-2088)
- W. Li
- X. B. Li (ORCID: https://orcid.org/0009-0006-8144-2725)
- Zhou Zhang (ORCID: https://orcid.org/0000-0001-9525-6938)
- Wenjie Li (ORCID: https://orcid.org/0009-0007-5015-068X)
- Cheng‐Lin Liu (ORCID: https://orcid.org/0000-0001-9032-2991)
- Hongmin Wang (ORCID: https://orcid.org/0000-0002-3597-3086)
- Feifei Fan (ORCID: https://orcid.org/0000-0002-5653-7654)
- Yu Zhao (ORCID: https://orcid.org/0000-0003-0831-3784)
Institutions
- Burning Rock Biotech (China) (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/cam4.70078
- Citations
- 4
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 1.14
Funders
- National Natural Science Foundation of China